Amgen, AstraZeneca bolster their case for breakthrough asthma program as FDA considers taking up a review

Just a few days after submitting a BLA for their highly-touted asthma program, Amgen and AstraZeneca released new data they hope will continue to strengthen their FDA pitch.

The companies released further detailed Phase III results for tezepelumab early Thursday morning, and published the full dataset...

Click to view original post